Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy

被引:5
|
作者
Zhao, Xin [1 ]
Li, Xinbao [2 ]
Lin, Yulin [2 ]
Ma, Ru [2 ]
Zhang, Ying [2 ]
Xu, Dazhao [2 ]
Li, Yan [1 ,2 ]
机构
[1] Peking Univ, Sch Clin Med 9, Dept Peritoneal Canc Surg, Beijing Shijitan Hosp, 10 Tieyi Rd,Yangfangdian St, Beijing 100038, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, Dept Peritoneal Canc Surg, Beijing, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 03期
关键词
Bayesian network; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; pseudomyxoma peritonei; survival prognostic model; NEOPLASMS; OUTCOMES;
D O I
10.1002/cam4.5138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives To establish a survival prognostic model for pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) based on Bayesian network (BN). Methods 453 PMP patients were included from the database at our center. The dataset was divided into a training set to establish BN model and a testing set to perform internal validation at a ratio of 8:2. From the training set, univariate and multivariate analyses were performed to identify independent prognostic factors for BN model construction. The confusion matrix, receiver operating characteristic (ROC) curve and the area under curve (AUC) were used to evaluate the performance of the BN model. Results The univariate and multivariate analyses identified 7 independent prognostic factors: gender, previous operation history, histological grading, lymphatic metastasis, peritoneal cancer index, completeness of cytoreduction and splenectomy (all p < 0.05). Based on independent factors, the BN model of training set was established. After internal validation, the accuracy and AUC of the BN model were 70.3% and 73.5%, respectively. Conclusion The BN model provides a reasonable level of predictive performance for PMP patients undergoing CRS + HIPEC.
引用
收藏
页码:2637 / 2645
页数:9
相关论文
共 50 条
  • [31] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report
    Ebbe Billmann Thorgersen
    Espen Melum
    Trine Folseraas
    Stein Gunnar Larsen
    Pål Dag Line
    World Journal of Surgical Oncology, 16
  • [32] Anaesthetic management of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective audit
    Shiralkar, S. P.
    Kerr, P.
    Scottt, J.
    Sivalingam, P.
    ANAESTHESIA AND INTENSIVE CARE, 2017, 45 (04) : 490 - 498
  • [33] Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms
    van Eden, W. J.
    Kok, N. F. M.
    Snaebjornsson, P.
    Jozwiak, K.
    Woensdregt, K.
    Bottenberg, P. D.
    Boot, H.
    Aalbers, A. G. J.
    BJS OPEN, 2019, 3 (03): : 376 - 386
  • [34] Thoracic Cytoreductive Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy for Pseudomyxoma Peritonei
    Chua, Terence C.
    Yan, Tristan D.
    Yap, Zhu L.
    Horton, Matthew D.
    Fermanis, Gary G.
    Morris, David L.
    JOURNAL OF SURGICAL ONCOLOGY, 2009, 99 (05) : 292 - 295
  • [35] ASO Author Reflections: Discordant Pathology in Pseudomyxoma Peritonei and Its Impact on Survival following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Godbole, Chintamani
    Memon, Ayaz Ahmed
    Carr, Norman John
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (04) : 2614 - 2615
  • [36] ASO Author Reflections: Discordant Pathology in Pseudomyxoma Peritonei and Its Impact on Survival following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Chintamani Godbole
    Ayaz Ahmed Memon
    Norman John Carr
    Annals of Surgical Oncology, 2022, 29 : 2614 - 2615
  • [37] Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: A prospective study
    Jess, Per
    Iversen, Lene H.
    Nielsen, Mette B.
    Hansen, Flemming
    Laurberg, Soren
    Rasmussen, Peter C.
    DISEASES OF THE COLON & RECTUM, 2008, 51 (06) : 868 - 874
  • [38] Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei
    Bjersand, Kathrine
    Mahteme, Haile
    Poromaa, Inger Sundstrom
    Andreasson, Hakan
    Graf, Wilhelm
    Larsson, Rolf
    Nygren, Peter
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S810 - S816
  • [39] Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei
    Kathrine Bjersand
    Haile Mahteme
    Inger Sundström Poromaa
    Håkan Andréasson
    Wilhelm Graf
    Rolf Larsson
    Peter Nygren
    Annals of Surgical Oncology, 2015, 22 : 810 - 816
  • [40] Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals
    Kitai, Toshiyuki
    Kawashima, Masahiro
    Yamanaka, Kenya
    Ichijima, Kunio
    Fujii, Hideaki
    Mashima, Susumu
    Shimahara, Yasuyuki
    SURGERY TODAY, 2011, 41 (09) : 1219 - 1223